Niagen Bioscience, Inc. (FRA:OCD1)

Market Cap	448.92M
Revenue (ttm)	106.29M
Net Income (ttm)	17.41M
Shares Out	n/a
EPS (ttm)	0.20
PE Ratio	25.78
Forward PE	28.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	5
Open	5.35
Previous Close	5.35
Day's Range	5.35 - 5.35
52-Week Range	4.72 - 12.40
Beta	n/a
RSI	48.30
Earnings Date	Mar 5, 2026

About Niagen Bioscience

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and ph...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1999
• Employees: 104
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OCD1

Financial Performance

Financial numbers in USD